Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior cycle 1, day 1
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 21 days prior to registration
Clinically significant ascites defined as requiring ? 1 paracentesis every 2- weeks
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to initiation of ABC294640
Ascites requiring active medical management including paracentesis
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to registration are NOT eligible for participation
Has ascites that requires frequent paracentesis or a pleural effusion that requires repeated thoracentesis
Ascites requiring active medical management, including paracentesis
Ascites requiring active medical management including paracentesis.
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
Subjects with pleural effusion requiring thoracentesis or ascites requiring paracentesis within 14 days prior to admission
Patients with ascites requiring paracentesis within 2 weeks prior to study entry (signature of informed consent) and during the screening period.
Ascites requiring active medical management including paracentesis.
Subjects with pleural effusions and/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently.
Pleural effusions requiring thoracentesis, or ascites requiring paracentesis, within 14 days prior to enrollment
Pleural effusions requiring thoracentesis within the 14 days prior to randomization
Ascites requiring paracentesis within the 14 days prior to randomization
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to the first day of treatment
No subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to cycle 1 day 1
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
History of recurrent ascites requiring paracentesis within 4 weeks of study day 1.
Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days of first dose
History of medically significant ascites requiring repetitive paracentesis
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to first dose.
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization.
Pleural effusions requiring thoracentesis or ascites requiring paracentesis
Pleural effusions requiring thoracentesis or ascites requiring paracentesis
Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
Ascites requiring paracentesis for symptom improvement